Clinical outcomes of influenza-like illness treated with Chinese herbal medicine: an observational study
- PMID: 32185959
Clinical outcomes of influenza-like illness treated with Chinese herbal medicine: an observational study
Abstract
Objective: To present and analyze treatments and clinical outcomes of Chinese patients with influenza-like illness.
Methods: We conducted a multi-site observational study from December 2009 to April 2010. Patients with influenza-like illness from 45 hospitals were enrolled. Patients received Chinese herbal medicine (CHM), conventional treatments, or CHM plus conventional treatments (combination treatment) according to the guidelines for influenza A/H1N1 2009 in China. The primary outcomes were the time to alleviation of symptoms and the incidence of complications. The secondary outcomes were the time until becoming afebrile, incidence of severe illness, testing negative on an influenza A viral test, and total medical fees.
Results: In total, 5967 patients were enrolled. The percentages of patients prescribed CHM alone, conventional treatment, and combination treatment were 27.8%, 5.1%, and 67.7%, respectively. There were no significant differences in the time to alleviation of symptoms, incidence of complications, time to becoming afebrile, or rate of severe illness among the CHM, conventional, and combination treatment groups. The rates of testing negative on the influenza virus A rapid test and H1N1 virus test were 90.3% and 76.3%, respectively. However, significant differences were found in the total medical fees among the three groups: CHM treatments were more economical than the other two treatments.
Conclusion: The efficacy of CHM for influenza-like illness was not different from that of conventional treatments, but it was more economical.
Keywords: Cost-benefit analysis; Drugs, Chinese Herbal; Influenza A virus, H1N1 subtype; Observational study;.
Similar articles
-
Menopause-related symptoms: traditional Chinese medicine vs hormone therapy.Altern Ther Health Med. 2011 Jul-Aug;17(4):48-53. Altern Ther Health Med. 2011. PMID: 22314633 Clinical Trial.
-
Natural herbal medicine Lianhuaqingwen capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial.Chin Med J (Engl). 2011 Sep;124(18):2925-33. Chin Med J (Engl). 2011. PMID: 22040504 Clinical Trial.
-
Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.Ann Intern Med. 2011 Aug 16;155(4):217-25. doi: 10.7326/0003-4819-155-4-201108160-00005. Ann Intern Med. 2011. PMID: 21844547 Clinical Trial.
-
Placebo-controlled trials of Chinese herbal medicine and conventional medicine comparative study.Int J Epidemiol. 2007 Oct;36(5):1086-92. doi: 10.1093/ije/dym119. Epub 2007 Jun 29. Int J Epidemiol. 2007. PMID: 17602184 Review.
-
Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma.J Ethnopharmacol. 2013 Oct 7;149(3):601-12. doi: 10.1016/j.jep.2013.07.030. Epub 2013 Aug 1. J Ethnopharmacol. 2013. PMID: 23916858 Review.
Cited by
-
An Update on Current Therapeutic Drugs Treating COVID-19.Curr Pharmacol Rep. 2020;6(3):56-70. doi: 10.1007/s40495-020-00216-7. Epub 2020 May 11. Curr Pharmacol Rep. 2020. PMID: 32395418 Free PMC article. Review.
-
Herbal Medication to Enhance or Modulate Viral Infections.Nurs Clin North Am. 2021 Mar;56(1):79-89. doi: 10.1016/j.cnur.2020.10.007. Epub 2020 Nov 28. Nurs Clin North Am. 2021. PMID: 33549288 Free PMC article. Review.
-
A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management.Front Pharmacol. 2021 Feb 26;12:576448. doi: 10.3389/fphar.2021.576448. eCollection 2021. Front Pharmacol. 2021. PMID: 33732150 Free PMC article. Review.
-
A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment.J Evid Based Integr Med. 2021 Jan-Dec;26:2515690X211003727. doi: 10.1177/2515690X211003727. J Evid Based Integr Med. 2021. PMID: 33761791 Free PMC article. Review.
-
SARS-CoV-2 and its new variants: a comprehensive review on nanotechnological application insights into potential approaches.Appl Nanosci. 2023;13(1):65-93. doi: 10.1007/s13204-021-01900-w. Epub 2021 Jun 10. Appl Nanosci. 2023. PMID: 34131555 Free PMC article. Review.
Grants and funding
LinkOut - more resources
Miscellaneous